Resistell proposes an alternative to culture based antibiogram, the current gold standard in antibiotic susceptibility testing. The firm's offering is a diagnostic device. The rapid AST method is based on the detection of movement caused by living bacterial cells. Because the test is growth independent rapid AST, Resistell reduces the time taken to get a result from days to minutes. The company provides information on which antibiotic should be used to treat the patient, and the concentration at which it should be administered.
- Invested amount